Results 91 to 100 of about 3,132 (216)

Therapeutic effect of faricimab in macular telangiectasia type 1 and Coats’ disease: case series

BMC Ophthalmology
Background To report the anatomical and functional outcomes of intravitreal faricimab injection in cases of macular telangiectasia type 1 and Coats’ disease that were refractory to previous treatments.
Hyun Young Park, Kwangsic Joo, Se Joon Woo   +2 more
doaj   +1 more source

Efficacy of faricimab for recalcitrant multifactorial cystoid macular edema

American Journal of Ophthalmology Case Reports
Purpose: More information is emerging on faricimab-svoa (faricimab) used for etiologies beyond wet age-related macular degeneration (AMD) and diabetic macular edema (DME), including ongoing trials for use in macular edema following retinal vein occlusion
Justin Hanson, Marcus Yamamoto, Edmund Tsui, Irena Tsui   +3 more
doaj   +1 more source

Faricimab efficacy in type 1 macular neovascularization: AI-assisted quantification of pigment epithelium detachment (PED) volume reduction over 12 months in Naïve and switch eyes

International Journal of Retina and Vitreous
This study evaluates the efficacy of intravitreal Faricimab in reducing pigment epithelium detachment (PED) and fluid volumes in both treatment-naïve eyes and eyes unresponsive to anti-VEGF mono-therapies, all diagnosed with type 1 macular ...
Jennifer Cattaneo, P. Forte, Giovanni Forte, C. Eandi   +3 more
semanticscholar   +1 more source

Faricimab-associated hypertensive uveitis - a case report

Background Faricimab (Vabysmo™, Roche/Genentech, Basel, Switzerland) is a humanized, bispecific monoclonal antibody which binds and inhibits both angiopoietin-2 and all vascular endothelial growth factor (VEGF)-A isoforms. It has been
Mario R. Romano, Andrea Nastasi, Riccardo Vinciguerra   +2 more
core   +1 more source

Safety Evaluation of Bilateral Same-Day Intravitreal Injection of Faricimab

Ophthalmology and Therapy
Introduction Intravitreal injection of anti-vascular endothelial growth factor (VEGF) agents is the most commonly performed ophthalmic procedure. Many retinal specialists routinely perform same-day bilateral intravitreal anti-VEGF injections, in order to
Michael D. Karampelas, Irini P. Chatziralli, Dimitrios A. Karagiannis   +2 more
doaj   +1 more source

Faricimab for neovascular age-related macular degeneration and diabetic macular edema: from preclinical studies to phase 3 outcomes

Graefe's Archive for Clinical and Experimental Ophthalmology
Intravitreal anti–vascular endothelial growth factor (VEGF) therapy is the standard of care for diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD); however, vision gains and anatomical improvements are not sustained over
H. Agostini, Francis Abreu, C. Baumal, Dolly S. Chang, Karl G. Csaky, A. Demetriades, L. Kodjikian, Jennifer I. Lim, Philippe Margaron, J. Monés, T. Peto, F. Ricci, Matthias Rüth, Rishi P. Singh, I. Stoilov, Balakumar Swaminathan, Jeffrey R. Willis, Peter D. Westenskow   +17 more
semanticscholar   +1 more source

Short-term real-world outcomes of diabetic macular edema treated with intravitreal faricimab

PLoS ONE
Faricimab, a new drug for diabetic macular edema (DME), was made available in Japan in 2022. However, few reports have been published about its treatment outcomes in clinical practice.
Toshiaki Hirakata, Fumihiro Hara, Yuta Nochi, Daisuke Shinohara, Shutaro Yamamoto, Yoshimune Hiratsuka, S. Nakao   +6 more
semanticscholar   +1 more source

Faricimab-svoa

American Journal of Health-System Pharmacy, 2022
openaire   +2 more sources

Real-world treatment patterns and visual outcomes of faricimab in patients with diabetic macular oedema in the UK at 12 months: the FARWIDE-DMO study

Eye
The Faricimab Real-World Evidence (FARWIDE) studies are evaluating real-world outcomes of eyes with diabetic macular oedema (DMO)/neovascular age-related macular degeneration (nAMD) treated with faricimab in the UK.
T. Peto, I. Pearce, J. Talks, G. de Salvo, Praveen J. Patel, S. D. De Silva, Richard P. Gale, S. Sivaprasad, Deepali Varma, Rhianon Reynolds, C. Bailey, L. Downey, Christine A. Kiire, Gloria C. Chi, M. Dodds, N. James, Amanda Downey, Parul Dayal   +17 more
semanticscholar   +1 more source

Beyond Cost: Faricimab as a Driver of Service Efficiency and Quality in Neovascular Age-Related Macular Degeneration Care

Ophthalmology and Therapy
Introduction Neovascular age-related macular degeneration (nAMD) is a chronic, vision-threatening condition requiring ongoing anti-vascular endothelial growth factor (anti-VEGF) injections.
Yaneth Gil-Rojas, Luke Nicholson, Sebastien Eymere, Oliver Cox, Marloes Bagijn   +4 more
doaj   +1 more source